ArticleScientific reports2025
The relationship between hemogram based inflammatory indices and prognosis in ectopic pregnancy cases treated with methotrexate.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inflammatory indices, machine learning and artificial intelligence in tubal ectopic pregnancy management.Turkish journal of obstetrics and gynecology · 2026Article
- The Predictive Value of Systemic Inflammatory Markers from Failed Single-Dose Methotrexate Therapy in Tubal Ectopic Pregnancy: A Retrospective Single-Center Study.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the effectiveness of β-hCG levels and inflammatory indices (NLR, MLR, PLR, and SII) in predicting rupture risk and treatment success in ectopic pregnancies treated with methotrexate (MTX). A retrospective analysis was conducted between 2017 and 2024 at Kütahya Health Sciences University, including 85 patients diagnosed with ectopic pregnancy. The diagnosis was confirmed by transvaginal ultrasonography. Patients with non-tubal ectopic pregnancies, active infections, autoimmune diseases, or organ failure were excluded. Demographic data, β-hCG levels (at admission, treatment day, and days 4 and 7), and inflammatory parameters were recorded. ROC analysis was used to assess rupture risk, with significance set at p < 0.05. The mean age was 32.1 ± 6.3 years, and the mean BMI was 24.95 ± 3.87 kg/m². Post-treatment β-hCG levels were significantly higher in rupture cases: 10178.7 ± 11236.1 mIU/mL on day 4 and 9671.9 ± 10468.7 mIU/mL on day 7. ROC analysis yielded an AUC of 0.753 (cut-off: 2480.5 mIU/mL) on day 4 and 0.815 (cut-off: 1295.0 mIU/mL) on day 7, with sensitivities of 70% and specificities of 70% and 74%, respectively. NLR, MLR, PLR, and SII showed no significant predictive values. Hospitalization was longer in the surgical group (7.9 ± 5.8 days) compared to methotrexate-only cases (5.8 ± 3.9 days). β-hCG levels are reliable biomarkers for predicting rupture risk in ectopic pregnancies. Regular monitoring reduces surgical intervention and supports personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.